Equities

Shield Therapeutics PLC

Shield Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.75
  • Today's Change-0.10 / -5.41%
  • Shares traded3.82m
  • 1 Year change-74.07%
  • Beta1.6022
Data delayed at least 20 minutes, as of May 17 2024 16:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.

  • Revenue in GBP (TTM)13.09m
  • Net income in GBP-33.29m
  • Incorporated2015
  • Employees73.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bivictrix Therapeutics PLC0.00-2.33m9.49m10.00--2.68-----0.0352-0.03520.000.04280.00----0.00-50.56---57.49--------------0.1267-------6.71------
Cambridge Nutritional Sciences PLC9.05m-3.21m9.52m91.00--1.02--1.05-0.0136-0.01050.03850.03910.58573.972.0599,406.59-20.81-10.49-23.88-11.9052.9059.24-35.53-27.404.22-128.470.0225---11.63-1.96-125.12---45.83--
Kanabo Group PLC895.00k-7.99m10.12m20.00--1.35--11.31-0.0137-0.01370.00170.01190.078511.1128.41---70.12-75.83-77.61-83.3314.97---893.30-1,267.354.96-10.430.035--48.42---16.26------
Synairgen plc0.00-9.99m11.60m30.00--0.7266-----0.0496-0.04960.000.07930.00----0.00-41.40-54.75-48.86-60.72-------83,247.62----0.00------63.74--0.00--
Proteome Sciences plc5.03m-2.44m11.81m35.00------2.35-0.0083-0.00830.017-0.01040.42093.893.04143,657.10-20.45-1.22----32.7654.53-48.59-2.200.2667-2.031.29---35.3710.52-284.38--126.22--
Chill Brands Group PLC146.62k-3.64m12.40m2.00------84.60-0.0142-0.01420.0006-0.00240.03190.09920.363973,310.00-79.21-72.55-141.46-105.3553.05---2,485.30-1,625.460.6499-8.481.17---86.73-50.8923.50---35.95--
Provexis plc598.08k-496.59k13.58m2.00--13.54--22.70-0.0002-0.00020.00030.00040.67173.042.95299,040.00-55.78-48.82-41.86-33.6846.7286.14-83.03-97.641.96--0.00---8.5110.58-71.79------
Abingdon Health PLC5.34m-2.24m13.94m82.00--7.38--2.61-0.0184-0.01840.04390.01490.89787.674.7465,170.73-37.55-51.31-58.04-79.8557.3533.16-41.82-139.641.59--0.3572--42.68--83.77------
Shield Therapeutics PLC13.09m-33.29m14.47m73.00--0.9624--1.11-0.0458-0.04580.01810.01920.3473.651.31179,246.60-88.29-56.68-136.30-67.4430.7852.20-254.44-365.892.04-30.010.5739--137.951.9533.13---2.50--
Genincode PLC1.72m-6.73m15.48m28.00--1.76--9.02-0.0703-0.07030.01790.04970.16816.362.8861,285.71-65.92---72.37--47.55---392.31--5.85--0.0632--23.92---34.21------
Destiny Pharma PLC0.00-5.66m15.49m19.00--1.68-----0.0624-0.06240.000.09650.00----0.00-60.33-54.32-67.28-59.97------------0.00------13.02--35.39--
LungLife AI Inc36.32k-4.27m15.81m15.00--0.8784--435.41-0.1677-0.16770.00140.24510.0038--0.28312,421.20-44.11---50.09--100.00---11,767.39------0.0419--91.67--28.83------
OptiBiotix Health PLC689.10k-13.17m17.63m3.00--1.75--25.58-0.1489-0.14890.00780.10290.04262.281.25229,700.00-81.3517.83-83.4318.6649.3154.87-1,911.88190.543.24-0.0890.00---79.3519.05-58.686.2830.03--
Oncimmune Holdings PLC1.15m-6.15m18.16m56.00--27.65--15.77-0.08590.05070.01590.00890.12391.080.5941---66.15---131.46--68.75---533.94--3.75-1.960.8897--------------
Incanthera PLC0.00-1.48m18.86m8.00---------0.0192-0.01920.00-0.00860.00----0.00-373.20-101.74---132.88---------------------36.11------
Skinbiotherapeutics PLC161.65k-2.88m19.54m11.00--5.08--120.86-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
Data as of May 17 2024. Currency figures normalised to Shield Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

32.36%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Advisors (UK) Ltd.as of 18 May 202344.97m5.75%
Jupiter Asset Management Ltd.as of 21 Jul 202334.13m4.36%
Hargreaves Lansdown Asset Management Ltd.as of 05 May 202333.97m4.34%
IG Markets Ltd.as of 08 Feb 202430.05m3.84%
Premier Fund Managers Ltd.as of 05 May 202330.00m3.84%
LGT Capital Partners AG (Investment Management)as of 08 Feb 202428.70m3.67%
KW Investment Management Ltd.as of 08 Feb 202418.60m2.38%
Maitland Asset Management (Pty) Ltd.as of 08 Feb 202411.09m1.42%
Jarvis Investment Management Ltd.as of 08 Feb 202410.92m1.40%
Killik & Co. LLPas of 05 May 202310.62m1.36%
More ▼
Data from 30 Jun 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.